KHTRF (Knight Therapeutics) E10: $0.06 (As of Mar. 2026)


KHTRF Knight Therapeutics Inc KHTRF
71 GF Score
Price $6.99
GF Value $6.16
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Knight Therapeutics E10?

Knight Therapeutics KHTRF 71 E10 is $0.06 as of Mar. 2026. GuruFocus rates KHTRF with a GF Score™ of 71/100 and a GF Value™ of $6.16 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Knight Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was $0.095. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.06 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Knight Therapeutics's average E10 Growth Rate was -18.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-08), Knight Therapeutics's current stock price is $6.99. Knight Therapeutics's E10 for the quarter that ended in Mar. 2026 was $0.06. Knight Therapeutics's Shiller PE Ratio of today is 116.50.

During the past 13 years, the highest Shiller PE Ratio of Knight Therapeutics was 117.17. The lowest was 10.14. And the median was 50.82.


Knight Therapeutics  (OTCPK:KHTRF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Knight Therapeutics's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=6.99/0.06
=116.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Knight Therapeutics was 117.17. The lowest was 10.14. And the median was 50.82.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Knight Therapeutics E10 Related Terms


Knight Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Knight Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics E10 Chart

Knight Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.31 0.09 0.06

Knight Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.07 0.05 0.06 0.06

KHTRF vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Shiller PE Ratio falls into.


KHTRF
71GF Score
Knight Therapeutics Inc KHTRF
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Knight Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Knight Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.095/132.2623*132.2623
=0.095

Current CPI (Mar. 2026) = 132.2623.

Knight Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 0.030 102.002 0.039
201609 0.031 101.765 0.040
201612 0.045 101.449 0.059
201703 0.030 102.634 0.039
201706 0.002 103.029 0.003
201709 0.020 103.345 0.026
201712 0.038 103.345 0.049
201803 0.039 105.004 0.049
201806 0.021 105.557 0.026
201809 0.069 105.636 0.086
201812 0.002 105.399 0.003
201903 0.030 106.979 0.037
201906 0.099 107.690 0.122
201909 -0.016 107.611 -0.020
201912 -0.038 107.769 -0.047
202003 -0.007 107.927 -0.009
202006 0.098 108.401 0.120
202009 0.106 108.164 0.130
202012 0.047 108.559 0.057
202103 0.024 110.298 0.029
202106 0.188 111.720 0.223
202109 -0.055 112.905 -0.064
202112 -0.047 113.774 -0.055
202203 -0.126 117.646 -0.142
202206 0.016 120.806 0.018
202209 0.007 120.648 0.008
202212 -0.096 120.964 -0.105
202303 -0.029 122.702 -0.031
202306 0.015 124.203 0.016
202309 0.067 125.230 0.071
202312 -0.171 125.072 -0.181
202403 -0.030 126.258 -0.031
202406 -0.015 127.522 -0.016
202409 0.000 127.285 0.000
202412 0.070 127.364 0.073
202503 0.014 129.181 0.014
202506 -0.095 129.892 -0.097
202509 -0.029 130.287 -0.029
202512 0.065 130.366 0.066
202603 0.095 132.262 0.095

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $0.06 mean?
Knight Therapeutics (KHTRF) has a E10 of $0.06 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Knight Therapeutics and its competitors.
Is Knight Therapeutics' E10 too high?
Knight Therapeutics' current E10 is $0.06. Overall, Knight Therapeutics has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' E10 compare to ZTS and UTHR?
Knight Therapeutics' E10 of $0.06 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Knight Therapeutics and its competitors. Knight Therapeutics's current E10 is $0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (KHTRF) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.16, compared to a current price of $6.99 — trading 13.5% above its estimated fair value. The current E10 is $0.06. Knight Therapeutics' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Knight Therapeutics (KHTRF), the current E10 is $0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (KHTRF) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of $6.99 is trading 13.5% above its estimated GF Value™ of $6.16. GuruFocus considers Knight Therapeutics to be Modestly Overvalued.

Key valuation signals for KHTRF:

  • E10: $0.06
  • GF Value™: $6.16 vs. price of $6.99 (13.5% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the KHTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Knight Therapeutics Business Description

Other Exchanges GUD:Canada
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
71GF Score

Get the complete analysis for KHTRF

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.99
Price
$6.16
GF Value